- Home
- PCYO vs EDIT Comparison
PCYO vs EDIT Comparison
Compare PCYO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- EDIT
- Stock Information
- Founded
- PCYO 1976
- EDIT 2013
- Country
- PCYO United States
- EDIT United States
- Employees
- PCYO N/A
- EDIT N/A
- Industry
- PCYO Water Supply
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCYO Utilities
- EDIT Health Care
- Exchange
- PCYO Nasdaq
- EDIT Nasdaq
- Market Cap
- PCYO 244.4M
- EDIT 263.7M
- IPO Year
- PCYO N/A
- EDIT 2016
- Fundamental
- Price
- PCYO $11.13
- EDIT $2.76
- Analyst Decision
- PCYO
- EDIT Buy
- Analyst Count
- PCYO 0
- EDIT 12
- Target Price
- PCYO N/A
- EDIT $5.40
- AVG Volume (30 Days)
- PCYO 32.6K
- EDIT 1.8M
- Earning Date
- PCYO 07-09-2025
- EDIT 11-03-2025
- Dividend Yield
- PCYO N/A
- EDIT N/A
- EPS Growth
- PCYO 123.89
- EDIT N/A
- EPS
- PCYO 0.56
- EDIT N/A
- Revenue
- PCYO $27,447,000.00
- EDIT $38,901,000.00
- Revenue This Year
- PCYO N/A
- EDIT N/A
- Revenue Next Year
- PCYO N/A
- EDIT N/A
- P/E Ratio
- PCYO $19.68
- EDIT N/A
- Revenue Growth
- PCYO 40.36
- EDIT N/A
- 52 Week Low
- PCYO $9.65
- EDIT $0.91
- 52 Week High
- PCYO $14.63
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- PCYO 69.81
- EDIT 54.36
- Support Level
- PCYO $10.00
- EDIT $2.39
- Resistance Level
- PCYO $10.37
- EDIT $2.72
- Average True Range (ATR)
- PCYO 0.29
- EDIT 0.16
- MACD
- PCYO 0.10
- EDIT 0.00
- Stochastic Oscillator
- PCYO 97.13
- EDIT 71.54
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.